Key Challenges in Treating Multiple Myeloma in Taiwan
Key Challenges in Treating Multiple Myeloma in Taiwan
Created using ChatSlide
This keynote examines the rising burden of multiple myeloma in Taiwan, where aging populations and lagging survival rates highlight critical gaps in frontline access and high-risk cytogenetics management. Amidst evolving TE vs TIE paradigms and conditional NHI coverage, we spotlight unmet needs—frailty, toxicity, and sequencing—and emerging therapies like CAR-T and quadruplets. A call to action advocates for Dara-Rd reimbursement and tailored strategies to improve outcomes across all patient...